© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
The cardiovascular effects of erythropoietin
Sections of Cardiology and Nephrology, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA
dsane{at}wfubmc.edu
* Corresponding author. Tel.: +1-336-716-7533; fax: +1-336-716-9188.
Erythropoietin is a hypoxia-induced hormone that is essential for normal erythropoiesis. The production of recombinant human erythropoietin (rHuEpo) has revolutionized the treatment of anemia associated with chronic renal failure and chemotherapy, and has been used as prophylaxis to prevent anemia after surgery. The erythropoietin receptor is widely distributed in the cardiovascular system, including endothelial cells, smooth muscle cells and cardiomyocytes. Epo has potentially beneficial effects on the endothelium including anti-apoptotic, mitogenic and angiogenic activities. On the other hand, some reports suggest that rHuEpo may have pro-thrombotic or platelet-activating effects. Hypertension develops in 20–30% of renal patients treated with rHuEpo. Many patients with heart failure have anemia. Despite some potential adverse effects, early studies in heart failure patients with anemia suggest that rHuEpo therapy is safe and effective in reducing left ventricular hypertrophy, enhancing exercise performance and increasing ejection fraction. Further studies are warranted to define the role of rHuEpo in chronic heart failure and other cardiovascular settings.
KEYWORDS Angiogenesis; Endothelial function; Platelets; Renal function; Thrombosis/embolism
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Smith, D. Semple, S. Bhandari, and A.-M. L. Seymour Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail, August 1, 2009; 11(8): 732 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Doyle, C. S. Rihal, D. A. Gastineau, and D. R. Holmes Jr Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention implications for contemporary practice. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2019 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Toda, K. Ayajiki, and T. Okamura Cerebral Blood Flow Regulation by Nitric Oxide: Recent Advances Pharmacol. Rev., March 1, 2009; 61(1): 62 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Elfar, J. A. Jacobson, J. E. Puzas, R. N. Rosier, and M. J. Zuscik Erythropoietin Accelerates Functional Recovery After Peripheral Nerve Injury J. Bone Joint Surg. Am., August 1, 2008; 90(8): 1644 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. van Albada, G. J. du Marchie Sarvaas, J. Koster, M. C. Houwertjes, R. M. F. Berger, and R. G. Schoemaker Effects of erythropoietin on advanced pulmonary vascular remodelling Eur. Respir. J., January 1, 2008; 31(1): 126 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joyeux-Faure Cellular Protection by Erythropoietin: New Therapeutic Implications? J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 759 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis and A. Kanderian Anemia and Heart Failure: A New Pathway? J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1666 - 1667. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lindenblatt, M. D. Menger, E. Klar, and B. Vollmar Darbepoetin-Alpha Does Not Promote Microvascular Thrombus Formation in Mice: Role of eNOS-Dependent Protection Through Platelet and Endothelial Cell Deactivation Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1191 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. d'Uscio, L. A. Smith, A. V. Santhanam, D. Richardson, K. A. Nath, and Z. S. Katusic Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin Hypertension, May 1, 2007; 49(5): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fandrey A cordial affair - erythropoietin and cardioprotection Cardiovasc Res, October 1, 2006; 72(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hamed, I. Barshack, G. Luboshits, D. Wexler, V. Deutsch, G. Keren, and J. George Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy Eur. Heart J., August 1, 2006; 27(15): 1876 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation, June 13, 2006; 113(23): 2713 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Schafer Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood, June 1, 2006; 107(11): 4214 - 4222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Caramuru, A. A. Lopes, N. Y. Maeda, V. D. Aiello, and C. C. Filho Long-term Behavior of Endothelial and Coagulation Markers in Eisenmenger Syndrome Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 175 - 183. [Abstract] [PDF]
|
|
|
|
|
|
T. Miki, T. Miura, T. Yano, A. Takahashi, J. Sakamoto, M. Tanno, H. Kobayashi, Y. Ikeda, M. Nishihara, K. Naitoh, et al. Alteration in Erythropoietin-Induced Cardioprotective Signaling by Postinfarct Ventricular Remodeling J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 68 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moon, M. Krawczyk, D. Paik, T. Coleman, M. Brines, M. Juhaszova, S. J. Sollott, E. G. Lakatta, and M. I. Talan Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 999 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Malkin, P. J. Pugh, J. N. West, E. J.R. van Beek, T. H. Jones, and K. S. Channer Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial Eur. Heart J., January 1, 2006; 27(1): 57 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Milano and R. Collomp Erythropoietin and neuroprotection: a therapeutic perspective Journal of Oncology Pharmacy Practice, December 1, 2005; 11(4): 145 - 149. [Abstract] [PDF]
|
|
|
|
|
|
J. George, E. Goldstein, A. Abashidze, D. Wexler, S. Hamed, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner Cardiovasc Res, November 1, 2005; 68(2): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Clark and J. G.F. Cleland Anemia and Chronic Heart Failure: Are We Asking the Right Questions? Circulation, September 20, 2005; 112(12): 1681 - 1683. [Full Text] [PDF]
|
|
|
|
 |
|
 J. George, S. Patal, D. Wexler, A. Abashidze, H. Shmilovich, T. Barak, D. Sheps, and G. Keren Circulating Erythropoietin Levels and Prognosis in Patients With Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers Arch Intern Med, June 13, 2005; 165(11): 1304 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Namiuchi, Y. Kagaya, J. Ohta, N. Shiba, M. Sugi, M. Oikawa, H. Kunii, H. Yamao, N. Komatsu, M. Yui, et al. High Serum Erythropoietin Level Is Associated With Smaller Infarct Size in Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, D. A. Morrow, R. P. Giugliano, P. B.J. Burton, S. A. Murphy, C. H. McCabe, C. M. Gibson, and E. Braunwald Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes Circulation, April 26, 2005; 111(16): 2042 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. O. Ventura and M. R. Mehra Improvement of heart failure after renal transplantation: The complex maze of cardio-renal interaction J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1061 - 1063. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Scalera, J. T. Kielstein, J. Martens-Lobenhoffer, S. C. Postel, M. Tager, and S. M. Bode-Boger Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial Cells: Role of Dimethylarginine Dimethylaminohydrolase J. Am. Soc. Nephrol., April 1, 2005; 16(4): 892 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aicher, A. M. Zeiher, and S. Dimmeler Mobilizing Endothelial Progenitor Cells Hypertension, March 1, 2005; 45(3): 321 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, E. Lipsic, R. H. Henning, R. A. de Boer, A. J.H. Suurmeijer, D. J. van Veldhuisen, and W. H. van Gilst Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury Eur J Heart Fail, December 1, 2004; 6(7): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Geiger, G. M. Fischberg, W. Chen, and L. Bernstein Stroke Risk and Tamoxifen Therapy for Breast Cancer J Natl Cancer Inst, October 20, 2004; 96(20): 1528 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A Bogoyevitch An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection Cardiovasc Res, August 1, 2004; 63(2): 208 - 216. [Abstract] [Full Text] [PDF]
|
|